Feasibility of using oxycarotenoids and blueberry extract in complex therapy of patients with a wet form of AMD
DOI:
https://doi.org/10.24144/2415-8127.2018.58.100-102Keywords:
age-related macular degeneration, oxycarotenoids, blueberry extract, anthocyanins, nutraceuticals.Abstract
An increase in the incidence of age-related macular degeneration (AMD) is an acute public health problem. The effect of oxycarotenoides, anthocyanins, and also a number of vitamins and minerals on the pathogenetic links in the development and progression of age-related macular degeneration led to the study of the clinical efficacy of the use of combined nutraceutical medications in combination with intravitreal injections of anti-VEGF factor and periodic vasoprotective, nootropic, retinal protective therapy in patients with AMD. That is why this work is supposed to evaluate the effectiveness of using combined nutraceuticals in complex therapy of wet form of AMD in order to prevent the progression of age-related macular degeneration. The results of the study indicate a significantly better stabilization effect of treatment in the patients of the main group who received the drug "Slezavit" as a dietary supplement to the dietary structure as an additional source of oxycarotenoids (lutein, zeaxanthin) and anthocyanins, as well as water and fat-soluble vitamins and micro-elements in the complex therapy of patients with a wet form of age-related macular degeneration.
References
Akuffo K, Nolan J, Howard A, Moran R, Stack J, Klein R, et al. Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration. Eye. 2015;29(7):902- 912.
Evans J, Lawrenson J. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database of Systematic Reviews. 2017;5:32-4.
Johnson E, Mcdonald K, Caldarella S, Chung H, Troen A, Snodderly D. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutritional Neuroscience. 2008;11(2):75-83.
Garther DC. Lutein and zeaxanthin – new perspectives for preservation of eye health. Clinical Ophthalmology. 2015;1:13-21.
Kiselyova TM, Lagutina YuM, Kravchuk OA. Influence of anthocyanosides on visual functions and hemodynamics of patients with non-exudative age-related macular degeneration. VI All-Russian school of ophthalmology. SB science. tr M. 2017:452-4.
Klein R, Meuer S, Myers C, Buitendijk G, Rochtchina E, Choudhury F, et al. Harmonizing the Classification of Age-related Macular Degeneration in the Three-Continent AMD Consortium. Ophthalmic Epidemiology. 2014;21(1):14-23.
Kon JY. Modern ideas about the role of lutein carotenoid in the nutrition of young children. Pediatrics. 2012;91(1):96-102.
Kumari N, Ruth E, Michael R. Carotenoids and co-antioxidants in age-related maculopathy: Design and Methods. Ophthalm. Epidemiol. 2013;15:389-401.
Latalska M, Matysik-Wouniak A, Bylina J. Wet age-related macular degeneration (wet AMD) in rural and urban inhabitants in south-eastern Poland. Ann. Agric Environ Med. 2013;19:726-30.
Matsunaga N, Chikaraishi Y, Shimazawa M, et al. () Vacciniummyrtillus (Bilberry) Extracts Reduce Angiogenesis In Vitro and In Vivo. Evid. Based Complement. Alternat. Med. 2014;7(1):47-56.
Novosti MOZ Ukraini. (2016) Available at:http://www.moz.gov.ua.
Romanenko IA. Effectiveness of Bilberry Preparations in Ophthalmology: Clinical Observations. Clinical Ophthalmology. 2011;1:32-38.
Saksonova EO Lutein and zeaxanthin are the main components of the antioxidant eye protection system. Clinical Ophthalmology. 2015;2:124-138.
Schmier JK, Covert DW, Lau EC.Patterns and costs associated with progression of age-related macular degeneration. Am. J.Ophthalmol. 2012;154(4):675-81.
Stavitskay TV. Extracts of Vaccinium myrtillus in the ophthalmology. Clinical Ophthalmology. 2013;3:86- 88.
Sun XD, Wang FH. Optimizing the individual treatment of neovascular age-related macular degeneration. Zhonghua Yan Ke Za Zhi. 2014;48(10):867-69.
Trieschmann M, Beatty S, Nolan J. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the Luna stady. Experimental Eye Reseach. 2017;84:718-28.
Wang H, Barteselli G, Freeman WR. Temporal pattern of resolution/reccurence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration. Int. J. Ophthalmol. 2013;6(5):600-5.
Huang Y, Dou H, Huang F, Xu X, Zou Z, Lu X, et al. Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial. British Journal of Ophthalmology. 2014;99(3):371-375.
